



## Oncogenetics of Colorectal Cancer

Guest Editors:

### Dr. Muhammad Kibriya

1. Institute for Population and Precision Health (IPPH), Biological Sciences Division, University of Chicago, Chicago, IL 60637, USA

2. Department of Public Health Sciences, Biological Sciences Division, University of Chicago, Chicago, IL 60637, USA

### Dr. Marc Bissonnette

Department of Medicine, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago, Chicago, IL 60637, USA

Deadline for manuscript submissions:

**closed (31 December 2024)**

### Message from the Guest Editors

Dear Colleagues,

Colorectal carcinoma (CRC) is one of the most common cancers worldwide. It represents a heterogeneous group of disorders from a molecular genomic point of view. Sporadic CRC is the most common form and is associated with somatic mutations, DNA methylation, genomic instability in the form of copy number changes, and microsatellite instability. Inflammatory pathways and host immune response have been associated not only with pathogenesis but also targeted therapeutic options. Many of the changes occurring are also reflected in liquid biopsy samples. Full use of known and yet-to-be-known molecular changes in the tumor tissue and/or liquid biopsy for predictive, diagnostic, therapeutic, and prognostic purposes could improve personalized therapy.

This Special Issue aims to focus on original research papers and review articles on different molecular genomic and epigenetic changes in CRC tissue and liquid biopsy and their association with the pathogenesis of CRC as well as therapeutic applications and outcomes.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)